Drug Profile
PDC 1421
Alternative Names: ABV 1504; ABV 1505; ABV-1601; BLI-1005; PDC-1421Latest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Medical and Pharmaceutical Industry Technology and Development Center
- Developer ABVC BioPharma; BioLite Inc; Cedars-Sinai Medical Center; Stanford University; Taipei Veterans General Hospital; University of California at San Francisco
- Class Antidepressants; Behavioural disorder therapies; Traditional Chinese medicine
- Mechanism of Action Norepinephrine plasma membrane transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Attention-deficit hyperactivity disorder; Major depressive disorder
- Preclinical Neurological disorders
Most Recent Events
- 14 Mar 2024 ABVC Biopharma has patent protection for "Polygala Extract for the Treatment of Attention-deficit hyperactivity disorder " in Taiwan
- 14 Mar 2024 ABVC Biopharma plans a End-of-Phase II meeting with the US FDA to finalize the protocol for phase III trials in Major depressive disorder
- 14 Mar 2024 ABVC Biopharma plans a phase I trial for Major depressive disorder in Q2 2024